Rationale: Mitochondrial signaling regulates both the acute and the chronic response of the pulmonary circulation to hypoxia, and suppressed mitochondrial glucose oxidation contributes to the apoptosis-resistance and proliferative diathesis in the vascular remodeling in pulmonary hypertension. Hypoxia directly inhibits glucose oxidation, whereas endoplasmic reticulum (ER)-stress can indirectly inhibit glucose oxidation by decreasing mitochondrial calcium (Ca 2+ m levels). Both hypoxia and ER stress promote proliferative pulmonary vascular remodeling. Uncoupling protein 2 (UCP2) has been shown to conduct calcium from the ER to mitochondria and suppress mitochondrial function.
T he role of mitochondria is increasingly being recognized in vascular health and disease 1 and is particularly critical in the pulmonary circulation. As recognized oxygen sensors, mitochondria form the basis of hypoxic pulmonary vasoconstriction, a feature of all mammals and the most important difference between the pulmonary and the systemic circulation (all systemic vessels dilate to hypoxia whereas pulmonary arteries constrict). 2 In response to acute decreases in oxygen levels, mitochondria alter the production of mitochondria-derived reactive oxygen species (mROS), which reach the cell membrane and regulate redox-sensitive voltage-gated potassium channels. The resulting voltage-gated potassium channels inhibition depolarizes the cell, increases influx of Ca 2+ into the cytoplasm, and causes contraction of pulmonary artery smooth muscle cells (PASMCs). 2 Mitochondria may also play an important role in the chronic hypoxic response and in pulmonary vascular disease via the regulation of the hypoxia inducible factor-1α (HIF1α). 3 Several aspects of the HIF1α axis are redox-sensitive, and α-ketoglutarate (αKG), a Krebs' cycle product, is an important cofactor in the hydroxylation reaction that destabilizes HIF1α. A primary suppression of mitochondrial glucose oxidation (GO) reduces mROS and αKG, activating HIF1α even in normoxia. 3 Aberrant HIF1α activation has been shown in normoxic animal and human pulmonary arteries in pulmonary hypertension (PHT). 4, 5 In cancer, where suppression of GO is critical for the apoptosis-resistance that characterizes most tumors, there is normoxic HIF1α activation. This pseudohypoxic HIF1α activation is reversed by activation of GO, decreasing cancer angiogenesis in vitro and in vivo. 3 Like in cancer, GO suppression also leads to apoptosis suppression and a proliferative diathesis that underlies the vascular remodeling in PHT. [6] [7] [8] Thus, it is possible that the HIF1α activation in PHT is also a consequence of suppressed mitochondrial signaling.
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The basis of GO suppression in PHT is unknown. Hypoxia, particularly if severe and sustained, directly inhibits GO by decreasing oxygen levels in mitochondria. Chronic hypoxia can inhibit GO by an additional, recently described mechanism: hypoxia, along with several conditions that trigger PHT, like viral infections or inflammation, causes endoplasmic reticulum (ER) stress. 8, 9 ER stress can lead to mitochondrial suppression by decreasing the influx of Ca 2+ from the ER to mitochondria because of an ER structural remodeling, decreasing mitochondrial Ca 2+ (Ca 2+ m ). This inhibits many Ca 2+ -dependent mitochondrial enzymes, including pyruvate dehydrogenase (PDH, the gate-keeper of GO) or isocitrate dehydrogenase and αKG dehydrogenase (both regulating αKG levels). [8] [9] [10] We hypothesized that uncoupling protein 2 (UCP2) deficiency could mimic the effects of hypoxia or ER stress on mitochondria in the pulmonary circulation. This is because UCP2 can function as a Ca 2+ channel in vascular mitochondria, facilitating influx of Ca 2+ from the ER to mitochondria. [11] [12] [13] UCP2, despite its name, does not seem to have uncoupling functions and has only modest homology to UCP1. [11] [12] [13] Mitochondria deficient in UCP2 may be deficient in Ca 2+ m and thus have suppressed GO in the absence of hypoxia or ER stress, inducing a pseudohypoxia and apoptosis-resistance state and predisposing to proliferative pulmonary vascular remodeling ( Figure 1 ). The description of human UCP2 polymorphisms leading to decreased gene expression makes this hypothesis more interesting and clinically relevant. 14
Methods
All experiments were performed with approval by the University of Alberta Committee on Animal Policy and Welfare. Mice were purchased from Jackson Laboratory and have previously been validated for effective Ucp2 knockout. 15 See the online Data Supplement for detailed methods.
In Vitro Experiments
Cell isolation, culture, and quantitative reverse transcriptasepolymerase chain reaction were performed using standard techniques as previously described. 7, 8 
Fluorescence Resonance Energy Transfer Analysis
PASMCs were transfected with the 4mtD3CPV cameleon plasmid, and Ca 2+ m was assessed as previously described under baseline 8 or histamine stimulation. 16 
Electron Microscopy
Cells were fixed with Karnovsky fixative, pelleted, and postfixed with 1% osmium tetroxide. Cells were then serially dehydrated in ethanol, rinsed in propylene oxide, and incubated in propylene oxide and resin before embedding resin. Samples were then sliced, mounted on metal gratings, and imaged on a Phillips EM 400T/ST transmission electron microscope.
Mass Spectroscopy
PASMCs were pelleted, suspended in 800 μL of ice-cold 80% methanol and 20% ddH 2 O and subjected to 2 freeze-thaw cycles. Centrifugation pelleted out cell debris and the supernatant was evaporated to obtain metabolites. Metabolites were resuspended in ddH 2 O and normalized to protein quantification. Seven microliters of sample were injected using a 4000 quadrupole-trap mass spectrometer (AB Sciex) equipped with a Ultra High Performance Liquid Chromatography 1290 system (Agilent) via SRM for Krebs' cycle intermediates.
PDH Activity
PDH activity was measured with a commercially available MitoProfile Dipstick assay kit (Mitosciences) as previously described. 8, 17 HIF1α Luciferase HIF1α transcriptional activity was performed with the HIF1α dualluciferase plasmid (SABiosciences) using Xfect transfection reagent (Clontech) and was assessed with the dual-luciferase reporter assay system (Promega) as previously described. 8, 17 
In Vivo Hemodynamic Assessments
Mice were randomized to normobaric hypoxia (10% O 2 ) or room air as previously described. 7, 8 Cardiac output was assessed on isofluraneanesthetized animals by echocardiography using the Vevo770 imaging system with a 707B (30MHz) probe. The cardiac output (CO) was calculated after determining the left ventricular outflow tract diameter, aortic velocity time integral, and heart rate using the formula: CO=7.85×LVOT 2 ×AoVTI×HR/10 000. Mean pulmonary artery pressures (mPAPs) were assessed in closed-chest animals with a Millar catheter (microtip, 1.4F; Millar Instruments Inc, Houston, TX) as previously described. 7, 8 Animals were placed in a supine position on a heated table under inhaled isoflurane anesthesia and the right jugular vein was cannulated and the catheter advanced into the pulmonary arteries. Pressures from the right atrium, right ventricle, and pulmonary arteries were also recorded continuously and mPAP was calculated electronically (Power Laboratory, with Chart software 5.4, ADInstruments). Total pulmonary resistance was calculated by the mPAP/CO ratio. Systemic blood pressure was assessed with the CODA2 (Kent Scientific Corp) mouse tail cuff system as previously described. 7, 8 
Histological Examination
Media wall thickness, muscularization, and medial proliferation were assessed using standard protocols as previously described. 7, 8 
Immunoblots
Tissues were collected and immunoblotting was performed as previously described. 7 
Whole Lung Respiration
Freshly isolated lungs from Ucp2WT and Ucp2KO mice were minced in 1 mL of Hanks buffer with 10 mmol/L glucose and placed in a sealed glass chamber (Warner Instruments) connected to a Strathkelvin 782 oxygen meter. Rate of oxygen consumption was calculated using the oxygen meter's software (version 4.0, Strathkelvin Instruments Ltd). Respiration rates were normalized to tissue weight.
Hematocrit
Blood was collected from isoflurane-anesthetized mice via cardiac puncture and injected into a RapidLab 348 blood gas analyzer (Bayer Healthcare).
Statistics
All values were expressed as mean±SEM. For in vitro analysis, differences were assessed by Student t test. Normality of our in vivo data were confirmed by the Shapiro-Wilk test. Intergroup differences were assessed by ANOVA using Fisher least square differences post hoc analysis. All analyses were performed using SPSS 19. Significance was considered at P<0.05.
Results
We isolated mitochondria from whole lung, spleen, and isolated PASMCs from resistance pulmonary arteries (>fourth division) of mice lacking Ucp2 (Ucp2KO) and their wildtype controls (Ucp2WT). The absence of UCP2 in KO mice PASMC was confirmed by quantitative reverse transcriptasepolymerase chain reaction (Online Figure IA ) and immunoblots (Online Figure IB) . UCP3, which may also influence ER-mitochondria calcium transfer, 11 did not differ between genotypes (Online Figure IB) . We then measured intra-Ca 2+ m in Ucp2WT-and Ucp2KO-PASMCs in normoxia and sustained hypoxia (48 hours). Fluorescence resonance energy transfer imaging showed that Ucp2KO-PASMCs had lower levels of Ca 2+ m than Ucp2WT-PASMCs under basal, normoxic conditions ( Figure 2A ). Unlike Ucp2WT-PASMCs, which had the expected Ca 2+ m reduction in hypoxia, 8 hypoxia did not further reduce Ca 2+ m in Ucp2KO-PASMCs (Figure 2A ). Similar results were obtained with the Ca 2+ m -sensitive dye Rhodamine-2 AM (Online Figure II) . Pharmacological UCP2 inhibition with genipin reduced Ca 2+ m in Ucp2WT-PASMCs but not Ucp2KO-PASMCs (Figure 2A ). Thus, UCP2 deficiency reduces Ca 2+ m in normoxic PASMCs, mimicking the effects of hypoxia and ER stress on PASMCs as previously published. 8, 9 To determine whether UCP2 facilitates Ca 2+ m uptake specifically from the ER in PASMCs, we analyzed Ca 2+ m on histamine-stimulation, which releases ER-calcium through inositol trisphosphate signaling. Experiments were performed in Ca 2+ -free solution to eliminate extracellular Ca 2+ sources. Figure 1 . A model of how uncoupling protein 2 (UCP2)-deficiency can mimic hypoxia-induced endoplasmic reticulum (ER) stress. UCP2 deficiency reduces calcium transfer from the ER (shown in blue) into the mitochondria (shown in red), which mimics the physical disruption of the ER-mitochondria unit caused by pulmonary hypertension-associated ER stress inducers like hypoxia, bone morphogenetic protein receptor type II (BMPRII), inflammation, or viruses. The mechanism and the consequences of such a hypoxia and ER stress-induced disruption of the ER-mitochondria unit was recently described by Sutendra et al 8 and Dromparis et al. 9 Reduced mitochondrial calcium (Ca 2+ m ) inhibits mitochondrial metabolic enzymes like pyruvate dehydrogenase (PDH) and some Krebs' cycle enzymes, lowers mitochondria-derived reactive oxygen species (mROS), and hyperpolarizes mitochondrial membrane potential (ΔΨm), suppressing apoptosis. Altered mitochondrial-derived signals activate transcription factors like hypoxia inducible factor-1α (HIF1α) and nuclear factor of activated T-cells (NFAT), potentiating the proproliferative and antiapoptotic signaling.
The histamine-induced increase in Ca 2+ m was blunted in Ucp2KO-PASMCs ( Figure 2B ). Inhibition of the Ca 2+ m uniporter with ruthenium red inhibited the responses similarly between genotypes, suggesting that the differences were not because of a potential Ca 2+ m uniporter downregulation. Chronically hypoxic PASMCs have ER stress-induced disruption of the normal communication between the ER and the mitochondria, including Ca 2+ exchange, because of an ER structural remodeling and an increase in the minimal distance between the 2 organelles. 8 Using transmission electron microscopy, we showed that the minimal ER-mitochondria distance was similar between Ucp2WT-and Ucp2KO-PASMCs under normoxia, suggesting that our observations cannot be attributed to ER-mitochondrial spatial remodeling ( Figure 2C ). In contrast, hypoxia increased the ER-mitochondria distance similarly in Ucp2WT-and Ucp2KO-PASMCs ( Figure 2C ). 8 In addition, the expression of glucose-regulated protein-78, which is upregulated in ER stress states in PASMCs, 8, 9 was not elevated in Ucp2KO-PASMCs, further supporting a lack of ER stress at normoxic baseline in these cells (Online Figure  III) . Evidence that spatial ER-mitochondria disruption in hypoxia does not further reduce Ca 2+ m in Ucp2KO-PASMCs (Figure 2A ) supports the fact that a lack of UCP2 in normoxia induces a pseudohypoxia state by maximally inhibiting ER-Ca 2+ m transport. In other words, a primary loss of UCPII or an ER stress-induced disruption of the ER-mitochondria unit may both, and via the same mechanism, result in a similar reduction of Ca 2+ m and GO. Several key metabolic enzymes are Ca 2+ m dependent, including PDH and the Krebs' cycle enzymes isocitrate dehydrogenase and αKG dehydrogenase. 10 PDH drives mitochondrial GO and its inhibition is associated with PHT. 17 m in response to histamine is calculated by the YFP/CFP ratio (right). The response to histamine is blunted in Ucp2KO-PASMC, whereas the ruthenium red inhibits the response to histamine by a similar degree in Ucp2WTand Ucp2KO-PASMC (n>15 cells/group; *P<0.05 compared with WT normoxic vehicle, +P<0.05 compared with KO normoxic vehicle). C, Transmission electron microscopy of Ucp2WT-and Ucp2KO-PASMCs (left) and minimum ER-mitochondrial distance (right; n=50 ERmitochondria contact points/group, * and +P<0.05 compared with normoxic controls). Arrows denote sites of ER-mitochondrial contact. M indicates mitochondria. July 5, 2013
In keeping with reduced Ca 2+ m , Ucp2KO-PASMCs had lower PDH activity than Ucp2WT-PASMCs ( Figure 3A ). PDH inhibition decreases the acetyl-CoA influx into the Krebs' cycle, while Krebs' cycle activity can be further decreased by isocitrate dehydrogenase and αKG dehydrogenase inhibition. Indeed, a metabolomics assessment of Krebs' cycle function showed reduced levels of many metabolites, including αKG, in Ucp2KO-PASMCs compared with the Ucp2WT-PASMCs under normoxia ( Figure 3B ). Once again, the reduction of Krebs' cycle metabolites in normoxic Ucp2KO-PASMCs (compared with wild type) was similar to the chronic hypoxiainduced reduction in Ucp2WT-PASMC metabolites. Thus, lack of UCPII mimics a hypoxic state and hypoxia does not cause a further suppression of mitochondrial function over and above what lack of UCPII does.
A similar pattern was present when we studied 2 other important indices of mitochondrial function: mROS, which are produced by the electron transport chain in proportion to Krebs' cycle-derived electron donors, and mitochondrial membrane potential (ΔΨm). Ucp2KO-PASMCs had lower levels of mROS and increased ΔΨm compared with Ucp2WT-PASMCs in normoxia ( Figure 3C ). The increased ΔΨm in Ucp2KO-PASMCs which, like the decreased mROS levels, is described in human and animal PHT-PASMC 6 and is in keeping with reduced mitochondrial levels of the positively charged Ca 2+ . Once again, normoxic Ucp2KO-PASMCs mimicked hypoxic Ucp2WT-PASMCs and hypoxia did not further suppress any tested parameter in Ucp2KO-PASMCs ( Figure 3A-3C) .
The hyperpolarized ΔΨm and the decreased mROS (both of which directly inhibit the opening of the voltage-and redox-gated mitochondrial transition pore, through which proapoptotic mediators like cytochrome c and apoptosis inducing factor efflux from the mitochondria) 19 promote an apoptosis-resistant state in both cancer 3, 18, 20 and PHT. 1, 7, 8, 17 To determine whether Ucp2KO-PASMCs are resistant to apoptosis, PASMCs were stressed in serum-starved conditions (0.1% fetal bovine serum). Apoptosis, measured by terminal dUTP nicked-end labelling, was increased in Ucp2WT-PASMCs, but not Ucp2KO-PASMCs ( Figure 3D ).
We then determined whether lack of UCPII could explain the activation of 2 transcription factors that have been shown to be critical in both hypoxic and in nonhypoxic PHT: HIF1α 4 and the nuclear factor of activated T-cells, cytoplasmic 2 (NFATc2). 21 On dismutation, mitochondria-produced superoxide becomes H 2 O 2 , a more stable and diffusible mROS that reaches several extramitochondrial targets, including voltage-gated potassium channels and transcription factors like HIF1α. Ucp2KO-PASMCs had reduced H 2 O 2 ( Figure 4A ) and αKG levels ( Figure 3B ), as well as normoxic HIF1αactivation, similar to hypoxic Ucp2WT-PASMCs. HIF1α activation was confirmed with measurement of nuclear HIF1α levels ( Figure 4B) , with direct measurement of its transcriptional activity using a dual-luciferase assay ( Figure 4B) , and by the mRNA expression of the HIF1α downstream target, Vegf (Online Figure IVA) . Ucp2KO-PASMCs had a reduced hydroxylated to total HIF1α ratio compared with Ucp2WT-PASMCs (Online Figure IVB) , suggesting that at least some of the inhibitory effects were through activation of prolyl hydroxylases, which hydroxylate and target HIF1α for degradation in an αKG-dependent manner. The activation of HIF1α in normoxic PASMCs lacking UCP2 was similar to that in hypoxic wild-type PASMCs and was maximal, as it was not increased further by hypoxia ( Figure 4B ).
Like HIF1α, NFATc2 is influenced (albeit indirectly) by mitochondrial signals. 21 Although dephosphorylation by the Ca 2+ -sensitive cytoplasmic enzyme calcineurin activates NFATc2, driving it to the nucleus, phosphorylation by the metabolic sensor glycogen synthase kinase-3β (GSK3β, which is inhibited when GO is suppressed in PASMCs 7 and cancer 20 ) results in nuclear export and transcriptional inhibition. Consistent with reduced mROS and inhibited voltagegated potassium channels, Ucp2KO-PASMCs had elevated levels of cytoplasmic Ca 2+ compared with Ucp2WT-PASMCs ( Figure 5A ). Moreover, Ucp2KO-PASMCs had elevated phosphorylated (inactive) GSK3β compared with Ucp2WT-PASMCs ( Figure 5B ). The increased cytoplasmic Ca 2+ and inhibited GSK3β were associated, as expected, with NFATc2 activation (increased nuclear levels) in normoxic Ucp2KO-PASMC, similar to hypoxic wild-type PASMCs ( Figure 5C ).
The activation of HIF1α, NFATc2, as well as the hyperpolarized ΔΨm and the decreased mROS and GO in Ucp2KO-PASMCs essentially create the cellular in vitro PASMC phenotype as has been shown in several human and animal PHT models. 1, 4, [6] [7] [8] [9] 17, 21 They promote proliferation and apoptosis-resistance and thus would be expected to cause PHT in normoxic mice in vivo. We thus measured mPAP and CO in close-chest anesthetized mice. Ucp2KO mice had elevated mPAP and total pulmonary resistance (total pulmonary resistance=mPAP/CO) compared with Ucp2WT controls ( Figure 6A and 6B; Online Figure V ), without differences in systemic blood pressure (Online Figure VI) . The elevated pressures resulted in a trend toward right ventricular (RV) hypertrophy, which did not reach significance (Online Figure  VII) . Lack of Ucp2 did not worsen pulmonary hemodynamic parameters on exposure to chronic hypoxia, a standard PHT model ( Figure 6A and 6B; Online Figure VI and VII), in keeping with our in vitro findings.
To confirm our in vitro studies to the whole organ level that is more relevant to our in vivo studies, we performed ex vivo lung respiration studies. Whole lung tissue from Ucp2KO mice had lower respiration rates (oxygen consumption) Figure VIII) , studied under identical conditions, in keeping with our in vitro studies that showed a suppression of several indices of mitochondrial activity.
To determine whether the hemodynamic changes were because of pulmonary vascular remodeling (as opposed to vasoconstriction), we examined the resistance pulmonary arteries of these mice in normoxia and hypoxia. Normoxic Ucp2KO mice had increased media thickness of resistance pulmonary arteries ( Figure 6C ). This was associated with increased nuclear levels of NFATc2 (Online Figure IX) and increased proliferation indices (Ki67) in smooth muscle actin-positive cells ( Figure 6D ). There was also increased arterial muscularization in Ucp2KO mice in normoxia, which was not exacerbated in hypoxia ( Figure 6E ). Taken together, these results indicated that the pulmonary vasculature in Ucp2KO mice resembles that of wild-type mice under chronic hypoxia. In addition, normoxic Ucp2KO mice have modestly, but significantly elevated hematocrit compared with Ucp2WT mice (Figure 6F ), suggesting that lack of Ucp2 mimics hypoxia in the kidney as well, where the HIF1α product erythropoietin is produced, inducing perhaps a global pseudohypoxia state.
Discussion
We show for the first time that the mitochondrial protein UCP2 is important in the vascular biology of the pulmonary circulation. We specifically show that lack of UCP2 causes a decrease in the entry of Ca 2+ from the ER to the mitochondria in PASMCs, resulting in decreased Ca 2+ m and a subsequent suppression of mitochondrial function. This suppression of mitochondrial function, and its associated metabolic switch toward glycolysis, has previously been shown to be critical for the proproliferative and antiapoptotic diathesis that characterizes the response of the pulmonary circulation to several triggers leading to PHT. 1, 4, [6] [7] [8] [9] 17, 21 The effects of UCP2 deficiency in PASMC mitochondria resemble the effects of hypoxia and ER stress as recently described. 8, 9 Lack of UCP2 induces a cellular and an in vivo phenotype that is identical to that caused by hypoxia as measured by several parameters, including the activation of HIF1α and NFATc2. Our results are in keeping with the work that has shown that UCP2 conducts Ca 2+ m and support the emerging metabolic hypothesis of pulmonary vascular oxygen sensing and PHT. 1, 6 The activity of the Ca 2+ -sensitive PDH is decreased in normoxic Ucp2KO-PASMCs (Figure 3A and 3B) and this has been shown in many PHT models, where the PDH activator small molecule dichloroacetate has been shown to reverse PHT. 4, 7, 22 PDH regulates the influx of pyruvate into the Krebs' cycle, stimulating the production of electron donors, electron transport chain activity, and thus the production of diffusible mediators like mROS or αKG. Overall, ROS production by PASMCs, particularly in response to acute hypoxia, has been a controversial issue likely relating to experimental conditions and the specific nature of the ROS measured in several studies. 2, [23] [24] [25] Nevertheless, our data herein are in keeping with several observations in human and animal pulmonary arterial hypertension that describe both a suppression of mitochondriaderived ROS and a hyperpolarization of mitochondria. 4, [7] [8] [9] 17, 21, 26 Yet, it is important to clarify that a decrease in mROS does not necessarily mean a decrease in the overall levels of cellular ROS produced by extramitochondrial sites in the cytoplasm and the cell membrane. Because mitochondrial function is overall suppressed in Ucp2-deficient cells, the decrease in mROS likely occurs through additional mechanisms, where PDH inhibition may be a contributing factor. Our data suggest that a potential deficiency of Ucp2 in humans could explain, at least in part, the PDH inhibition and perhaps the resulting suppression of GO and activation of glycolysis that has been described in patients with idiopathic pulmonary arterial hypertension. 7, 27 In humans, UCPII expression is influenced by recently described polymorphisms in the Ucp2 promoter. These polymorphisms, which decrease Ucp2 expression, are associated with increased incidence of atherosclerosis, 28 diabetic retinopathy, 29 and hypertension. 30 In animal models of UCP2 deficiency, however, the expression of the disease phenotype requires the exposure to predisposing conditions or triggers, consistent with the multifactorial nature of vascular disease. For example, mice lacking Ucp2 develop systemic hypertension only in appropriately stressed conditions, 31 and thus do not conflict with the normal systemic hemodynamics observed in our study. It is also intriguing that Ucp2 polymorphisms in humans are also associated with overall metabolic disturbances like obesity and diabetes mellitus, 14 whereas an unexplained insulin-resistance state has recently been described in patients with pulmonary arterial hypertension. 32 As the pulmonary vasculature exists in a much more oxidized environment and the PASMC mitochondria are different than the systemic vascular smooth muscle cell mitochondria (perhaps explaining why hypoxic pulmonary vasoconstriction is restricted to the pulmonary circulation), 33 the threshold for expressing a disease phenotype may be lower in the pulmonary arteries than in systemic vessels, explaining why PHT but not systemic hypertension is shown in normal/ baseline conditions in Ucp2KO mice.
The lack of UCP2 seems to cause HIF1α activation in PASMCs ( Figure 4B ; Online Figure IV ) and in the kidney, explaining the increased hematocrit in the Ucp2KO mice ( Figure 6F ). This activation in the pulmonary vasculature is believed to contribute to the enhanced glycolytic rates and glucose uptake that is apparent with lung 18-fluorodeoxyglucose-positron emission tomography in animal 34 and human pulmonary arterial hypertension. 27 The activation of HIF1α in rat and human pulmonary arterial hypertension tissues is well described but remains unexplained particularly because it often takes place in the absence of hypoxia. 4, 5 Our data suggest that the suppression of downstream mitochondrial signaling in cells lacking UCP2, including the decreased mROS and αKG levels, may explain this pseudohypoxic HIF1α activation. We have recently shown that in cancer cells (where HIF1α activation occurs even under normoxia) the suppression in mitochondrial function activates HIF1α by a mechanism that includes a prolyl-hydroxylasedependent mechanism (decrease in αKG production) and a prolyl-hydroxylase-independent mechanism (that involves mitochondrial H 2 O 2 -mediated regulation of p53 and inhibition of GSK3β). 3 Lack of UCP2 causes a direct decrease in H 2 O 2 ( Figure 4A ) and αKG production ( Figure 3B ) from mitochondria, as well as an indirect inhibition of GSK3β ( Figure 5B ) that follows the inhibition of GO, and thus the mechanism described in cancer cells can be applied to the PASMCs. Interestingly, HIF1α activation induces the expression of PDH kinase, a major inhibitor of PDH, thus causing inhibition of GO. 35 This has been used to suggest that the metabolic remodeling in cancer is a result, not a cause of HIF1α activation. Our current data, where the primary abnormality is in mitochondria (lack of UCP2), support a mitochondria-driven regulation of HIF1α. It is likely that both pathways are important and mitochondrial PDK and HIF1α activation are a part of positive feedback loop that promotes a sustained inhibition of GO and HIF1α activation even under normoxia.
Our data are also compatible with the discovery that epigenetic suppression of mitochondrial-specific superoxide dismutase can trigger normoxic HIF1α activation in the fawn-hooded rat, a model of spontaneous PHT. 26 Our observation that lack of UCP2 causes a decrease in the mitochondrial production of H 2 O 2 ( Figure 4A ) is similar to the effects of mitochondrial-specific superoxide dismutase inhibition that decreases H 2 O 2 , a diffusible mitochondria-derived redox mediator. In other words, both an epigenetic suppression of mitochondrial-specific superoxide dismutase or deficiency of other proteins that lead to suppression of mROS production, like UCP2 proposed here, can explain the intriguing observation of normoxic HIF1α in the pulmonary circulation and its role in promoting or predisposing to PHT.
The degree of spontaneous PHT that we found in the normoxic Ucp2 mice is modest, but it is important because spontaneous PHT (ie, without additional triggers like hypoxia, monocrotaline, or Sugen5146 with hypoxia) is very rare in animal models. This modest increase in mPAP may explain the absence of significant RV hypertrophy (Online Figure  VII) . Nevertheless, recent work suggests that Ucp2 is upregulated in RV pathobiology. 36 The fact that our mouse model was a global Ucp2 knockout, suggests that it is possible that Ucp2 may influence the development RV hypertrophy, which was beyond the scope of this study. Further studies are required to identify the precise or potential causal role of Ucp2 in RV hypertrophy.
A limitation of this study is that we focused on PASMC biology and did not address the role of UCPII in pulmonary artery endothelial cells. Nevertheless, it is now recognized that PHT pulmonary artery endothelial cells show similar metabolic remodeling to PASMCs, characterized by suppressed GO. 27 UCP2 has also been shown to regulate Ca 2+ m handling in vascular endothelial cells as well. [11] [12] [13] In other words, we speculate that pulmonary artery endothelial cells will have a similar to PASMC metabolism in the Ucp2KO mice.
We also did not explore the role of inflammation on PHT development in these mice. Indeed, inflammation may contribute to PHT-pathogenesis and Ucp2-deficient macrophages have basal activation of the proinflammatory transcription factor NFκB and exaggerated immune responses. 37 In humans, Ucp2 polymorphisms are also associated with autoimmune diseases, 38 a well-recognized feature of PHT. 17 Although we do not address a potential role of activated macrophages or other immune cells in the development of PHT in Ucp2KO mice, our in vitro studies and their agreement with the in vivo data suggest that a primary mechanism for spontaneous PHT is intrinsic to PASMCs. Importantly, the master transcription factor NFAT, which is activated both in inflammatory/immune cells and in PASMCs in the remodeled pulmonary circulation in both animal models and human PHT (promoting PASMC proliferation), 21 was also found to be activated in Ucp2KO-PASMCs in vivo and in vitro ( Figure 5C ; Online Figure IX ). This activation was compatible with both the increase in intracellular Ca 2+ and the decrease in the total/phosphorylated GSK3β ratio in Ucp2KO-PASMC ( Figure 5A and 5B) .
Because the Ucp2KO mouse model spontaneously develops PHT and also shares many of the mitochondria abnormalities described in many animal models and human PHT, it may be an important tool for future studies in the field. Clinical studies could explore whether Ucp2 polymorphisms contribute to PHT in humans, offering new biomarker and potentially therapeutic strategies. Our work does not prove a link between UCP2 and pulmonary arterial hypertension specifically, but may trigger future studies in this direction. However, our work may offer important clues for the mechanism that hypoxia causes PHT. The fact that hypoxia does not seem to have any additional effects to the PASMC over and above those induced by the lack of UCP2, suggests that chronic hypoxia may use the mitochondria calcium signaling system for its effects on the pulmonary circulation. Importantly, the fact that Ucp2KO mice have what seems to be a generalized pseudohypoxic environment makes them an attractive model for oxygensensing studies or for the effects of hypoxia on organs other than the lung as well.
